Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis

CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Source Type: research